Specialty drugs up share of per-capita spend as sales growth slows

As specialty growth looks set to plateau, the drug class continues to see its share of per-capita spending increase, with a decline in spending on traditional medicines creating space for more specialty share.

Want to Read More?

This content is available only to registered users. Log in to read the rest of this article or create a free account.

Login or Register to post a comment.